Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir

Gastroenterology

Volumn 151, Issue 5, 2016, Pages 973-985.e2

  Ramirez, Santseharay ^a   Mikkelsen, Lotte S ^a   Gottwein, Judith M ^a   Bukh, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Drug Evasion; In Vitro; Liver Disease; NUC

Indexed keywords

BECLABUVIR; DACLATASVIR; DASABUVIR; DELEOBUVIR; ELBASVIR; LEDIPASVIR; LOMIBUVIR; MERICITABINE; NESBUVIR; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; SOFOSBUVIR; UPRIFOSBUVIR; VELPATASVIR; ANTIVIRUS AGENT;

ADAPTATION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG POTENCY; GENETIC STABILITY; GENETIC TRANSFECTION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 3A; LIVER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNTRANSLATED REGION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; CELL CULTURE TECHNIQUE; CELL LINE; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HUMAN; PATHOGENICITY; PROCEDURES;

ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; SOFOSBUVIR;

EID: 84994813287     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.07.013     Document Type: Article

References (44)

1. 1 Mohd, H.K., Groeger, J., Flaxman, A.D., et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
2. 2 Perz, J.F., Armstrong, G.L., Farrington, L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006), 529–538.
3. 3 Ploss, A., Dubuisson, J., New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 61:Suppl 1 (2012), i25–i35.
4. 4 Smith, D.B., Bukh, J., Kuiken, C., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
5. 5 Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
6. 6 Webster, D.P., Klenerman, P., Dusheiko, G.M., Hepatitis C. Lancet 385 (2015), 1124–1135.
7. 7 Pawlotsky, J.M., New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146 (2014), 1176–1192.
8. 8 Goossens, N., Negro, F., Is genotype 3 of the hepatitis C virus the new villain?. Hepatology 59 (2014), 2403–2412.
9. 9 Lohmann, V., Korner, F., Koch, J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999), 110–113.
10. 10 Wakita, T., Pietschmann, T., Kato, T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005), 791–796.
11. 11 Lindenbach, B.D., Evans, M.J., Syder, A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005), 623–626.
12. 12 Li, Y.P., Ramirez, S., Gottwein, J.M., et al. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci U S A 109 (2012), E1101–E1110.
13. 13 Scheel, T.K., Gottwein, J.M., Mikkelsen, L.S., et al. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140 (2011), 1032–1042.
14. 14 Gottwein, J.M., Scheel, T.K., Jensen, T.B., et al. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141 (2011), 1067–1079.
15. 15 Li, Y.P., Ramirez, S., Humes, D., et al. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 146 (2014), 812–821.
16. 16 Li, Y.P., Ramirez, S., Jensen, S.B., et al. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci U S A 109 (2012), 19757–19762.
17. 17 Yamane, D., McGivern, D.R., Wauthier, E., et al. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20 (2014), 927–935.
18. 18 Ramirez, S., Li, Y.P., Jensen, S.B., et al. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology 59 (2014), 395–407.
19. 19 Li, Y.P., Ramirez, S., Mikkelsen, L., et al. Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77. J Virol 89 (2015), 811–823.
20. 20 Kim, S., Date, T., Yokokawa, H., et al. Development of hepatitis C virus genotype 3a cell culture system. Hepatology 60 (2014), 1838–1850.
21. 21 Svarovskaia, E.S., Dvory-Sobol, H., Parkin, N., et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 59 (2014), 1666–1674.
22. 22 Lam, A.M., Espiritu, C., Bansal, S., et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56 (2012), 3359–3368.
23. 23 Scheel, T.K., Gottwein, J.M., Carlsen, T.H., et al. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J Virol 85 (2011), 2891–2906.
24. 24 Carlsen, T.H., Pedersen, J., Prentoe, J.C., et al. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology 60 (2014), 1551–1562.
25. 25 Gottwein, J.M., Scheel, T.K., Callendret, B., et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 84 (2010), 5277–5293.
26. 26 Gottwein, J.M., Scheel, T.K., Hoegh, A.M., et al. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133 (2007), 1614–1626.
27. 27 Jensen, S.B., Serre, S.B., Humes, D.G., et al. Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother 59 (2015), 7426–7436.
28. 28 Pietschmann, T., Kaul, A., Koutsoudakis, G., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103 (2006), 7408–7413.
29. 29 Sakamoto, M., Akahane, Y., Tsuda, F., et al. Entire nucleotide sequence and characterization of a hepatitis C virus of genotype V/3a. J Gen Virol 75 (1994), 1761–1768.
30. 30 Hepatitis, C., guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
31. 31 European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
32. 32 Saeed, M., Andreo, U., Chung, H.Y., et al. SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524 (2015), 471–475.
33. 33 Pietschmann, T., Zayas, M., Meuleman, P., et al. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog, 5, 2009, e1000475.
34. 34 Kaul, A., Woerz, I., Meuleman, P., et al. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol 81 (2007), 13168–13179.
35. 35 Schmitt, M., Scrima, N., Radujkovic, D., et al. A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. J Virol 85 (2011), 2565–2581.
36. 36 DeGoey, D.A., Randolph, J.T., Liu, D., et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 57 (2014), 2047–2057.
37. 37 Liu, R., Curry, S., McMonagle, P., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59 (2015), 6922–6929.
38. 38 Lemm, J.A., Liu, M., Gentles, R.G., et al. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 58 (2014), 3485–3495.
39. 39 Kati, W., Koev, G., Irvin, M., et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59 (2015), 1505–1511.
40. 40 Dao Thi, V.L., Debing, Y., Wu, X., et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 150 (2016), 82–85.
41. 41 Hedskog, C., Dvory-Sobol, H., Gontcharova, V., et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat 22 (2015), 871–881.
42. 42 Wang, C., Sun, J.H., O'Boyle, D.R., et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 57 (2013), 2054–2065.
43. 43 Tong, X., Le, P.S., Li, L., et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 209 (2014), 668–675.
44. 44 Svarovskaia, E.S., Gane, E., Dvory-Sobol, H., et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213 (2016), 1240–1247.